ClinicalTrials.gg
CompletedNCT03594123Updated Nov 14, 2023Results posted

A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

A Phase 3 interventional study of Brexpiprazole and Brexpiprazole in Alzheimer's Disease, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 55 Years to 91 Years. Per ClinicalTrials.gov, last updated 2023-11-14.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
259
Allocation
Non-randomized
Ages
55 Years to 91 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd. — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Otsuka Holdings Co., Ltd..

Enrollment
7th of 12
259 · median 265
Started
2018
with 1 other
Phase 3
13 of 17
none open now
Registered
14th of 17
by date

Among the 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd., this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2018, is one of 13 in phase 3, and was the 14th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 91 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd., or all of them as a file.
02

Study summary

Active treatment extension study of the 331-14-213 trial, to assess the long-term safety and tolerability of oral brexpiprazole as treatment in adult participants with agitation associated with dementia of the Alzheimer's type (AAD).

03

Conditions studied

  • Alzheimer's Disease

Keywords

  • Agitation
04

Who can participate

Ages eligible
55 Years to 91 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have participated in the 331-14-213 study.
  • Participants must have an identified caregiver who has contact, at a minimum of 2 hours per day, 4 days per week to describe the participant's symptoms and can observe participant behavior.

Exclusion criteria

Exclusion Criteria:

  • Participants with a substantial protocol violation during the course of their participation in the double-blind trial 331-14-213.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
259 participants (actual)

Study arms

  • Experimental
    Prior Brexpiprazole

    Participants who received brexpiprazole in a previous double-blind phase 3 study (Trial 331-14-213 {NCT03548584}), received the same dose of brexpiprazole \[2 or 3 milligrams (mg)\], once daily (QD), orally, as they received during the previous study, for up to 12 weeks with dose adjustment.

    Drug: Brexpiprazole

  • Experimental
    Prior Placebo

    Participants who received placebo in a previous double-blind phase 3 study (Trial 331-14-213 {NCT03548584}), received brexpiprazole following a titration schedule, to gradually increase their dose from 0.5 mg QD, in the starting to 2 or 3 mg QD, orally, for up to 12 weeks with dose adjustment.

    Drug: Brexpiprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) by Severity

    An adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs with an onset date on or after the first dose of brexpiprazole. They are all adverse events that started after start of brexpiprazole; or if the event was continuous from baseline and was worsening, serious, study drug-related, or resulted in death, discontinuation, interruption, or reduction of study therapy. Adverse events were graded on a 3-point scale. The intensity of an adverse experience was defined as follows: 1 = Mild: Discomfort noticed, but no disruption to daily activity, 2 = Moderate: Discomfort sufficient to reduce or affect normal daily activity, and 3 = Severe: Inability to work or perform normal daily activity.

    Time frame: From first dose through 30 days after last dose of study drug (Up to approximately Week 16)

07

Results

Posted Nov 14, 2023

Participant flow

This study was conducted at 66 sites from 11 October 2018 to 19 September 2022 in the following countries: Bulgaria, Hungary, Serbia, Slovakia, Spain, Ukraine, and the United States.

Participant flow — Overall Study
MilestonePrior BrexpiprazolePrior Placebo
Started16396
Efficacy sample:15995
Completed14287
Not completed219
Withdrew: Lost to follow-up01
Withdrew: Adverse event85
Withdrew: Site terminated by sponsor41
Withdrew: Subject withdrew consent to participate71
Withdrew: Lack of efficacy10
Withdrew: Other (not related to covid-19)11

Outcome measures

PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) by Severity

An adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs with an onset date on or after the first dose of brexpiprazole. They are all adverse events that started after start of brexpiprazole; or if the event was continuous from baseline and was worsening, serious, study drug-related, or resulted in death, discontinuation, interruption, or reduction of study therapy. Adverse events were graded on a 3-point scale. The intensity of an adverse experience was defined as follows: 1 = Mild: Discomfort noticed, but no disruption to daily activity, 2 = Moderate: Discomfort sufficient to reduce or affect normal daily activity, and 3 = Severe: Inability to work or perform normal daily activity.

Time frame:
From first dose through 30 days after last dose of study drug (Up to approximately Week 16)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) by Severity
percentage of participantsPrior BrexpiprazolePrior Placebo
Mild20.913.5
Moderate9.219.8
Severe3.10

Adverse events

Collected over From first dose through 30 days after last dose of study drug (Up to approximately Week 16). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prior Brexpiprazole0/163 (0%)6/163 (3.7%)0/163 (0%)
Prior Placebo0/96 (0%)0/96 (0%)5/96 (5.2%)
Most frequent serious events
Most frequent serious events
EventPrior BrexpiprazolePrior Placebo
FallInjury, poisoning and procedural complications3/1630/96
Blood Loss AnaemiaBlood and lymphatic system disorders1/1630/96
HaemorrhoidsGastrointestinal disorders1/1630/96
Femur FractureInjury, poisoning and procedural complications1/1630/96
Hip FractureInjury, poisoning and procedural complications1/1630/96
Hepatic Enzyme IncreasedInvestigations1/1630/96
SyncopeNervous system disorders1/1630/96
Most frequent other events
Most frequent other events
EventPrior BrexpiprazolePrior Placebo
NasopharyngitisInfections and infestations0/1635/96

Baseline characteristics

Randomized sample comprised of all participants randomized into this trial. As prespecified in the SAP, data was analyzed based on the treatments (Brexpiprazole or Placebo) received in parent study 331-14-213. Participants received brexpiprazole 2 or 3 mg or placebo in the parent study, data for this study was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.

Age, Continuous
Age, Continuous(years)Prior BrexpiprazolePrior PlaceboTotal
Mean74.8 ± 7.973.4 ± 73.074.3 ± 75.0
Sex: Female, Male
Sex: Female, Male(Participants)Prior BrexpiprazolePrior PlaceboTotal
Female9946145
Male6450114
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Prior BrexpiprazolePrior PlaceboTotal
Hispanic or Latino523082
Not Hispanic or Latino11166177
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Prior BrexpiprazolePrior PlaceboTotal
American Indian or Alaska Native000
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American718
White15494248
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Prior BrexpiprazolePrior PlaceboTotal
Bulgaria151126
Hungary325
Serbia9817
Slovakia538
Spain538
Ukraine553186
United States7138109
08

Study locations

1 site
  • For additional information regarding sites, contact 844-687-8522
    Miami, Florida 33155, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Sep 2022, 47 months.

Results were first posted in Nov 2023, 1 year 1 month after primary completion.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 47 months is above that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2018
First posted
Jul 20, 2018
StartActual
Oct 11, 2018
Primary completionActual
Sep 19, 2022
CompletionActual
Sep 19, 2022
Results first posted
Nov 14, 2023
Last update
Nov 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03594123
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Jul 20, 2018
Start date
Oct 11, 2018
Primary completion
Sep 19, 2022
Completion
Sep 19, 2022
Results posted
Nov 14, 2023
Last update
Nov 14, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion